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Aim: In the search for evidence-based follow-up of 
patients after resection for colorectal cancer, numerous 
tumor markers have been proposed. This review has 
evaluated these markers and comments on the diagnos-
tic accuracy in finding recurrent disease in relation to 
Carcino-Embryonic Antigen (CEA). 
Methods: A comprehensive literature review (1985-
2010) was performed by two independent reviewers. 
Sensitivity and specificity of markers mentioned in the 
articles were checked by recalculation. A validated 
quality score system was used to estimate study qual-
ity. 
Results: Seventeen studies focusing on eight different 
markers were included. Three markers were shown to 
have comparable or better accuracy than CEA: TPA, 
CA 242 and CA 72-4 in at least one study. These three 
markers, from four independent studies, showed a tu-
mor marker sensitivity of > 60% in combination with 
an outperformance of CEA in follow-up. These results 
were not confirmed by six other studies investigating 
the same markers. 
Conclusion: This review revealed three tumor markers 
other than CEA that have been shown to adequately 
indicate recurrences in colorectal cancer. However, 
comparability of studies was difficult. Therefore a pro-
spective study of these markers seems necessary to 
investigate their real value, and to overcome design 
and inclusion biases. 
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Tumor markers in finding recurrent disease in colorectal cancer: a 
diagnostic review 
Introduction 
 
In colorectal cancer (CRC), 30-50% of patients will 
relapse after primary surgery with local recurrence or 
metastatic disease, mainly in the first two to three 
years after resection. After curative treatment, patients 
will be in follow-up in order to detect recurrent disease 
as early as possible. Early detection of recurrent tumor 
activity results in better chances of curation than late 
detection, and intended curative treatment of metasta-
ses is associated with higher survival rates than pallia-
tive treatment (Gomez et al. 2010).  
 Because of the wide variation in the follow-up 
programs used, a systematic review and meta-analysis 
failed to define the best combination and frequency of 
clinical visits, laboratory blood tests, endoscopic pro-
cedures and radiological investigations (Jeffery et al. 
2007). This paper focuses on laboratory biomarkers 
used in follow-up for colorectal cancer. Diagnostic 
accuracy of a tumor marker depends upon its sensitiv-
ity and specificity. In follow-up, tumor markers should 
ideally have high sensitivity with a low false-positive 
rate.   
 The best known serum tumor marker used in 
follow-up is Carcino-Embryonic Antigen (CEA), dis-
covered in 1965. Several studies showed that the pre-
operative CEA value correlates with prognosis after 
treatment (El-Awady et al. 2009, Wiratkapun et al. 
2001). Serum CEA has been the most sensitive diag-
nostic tool in asymptomatic patients for early diagnosis 
of recurrent disease in CRC and its use is proposed in 
several international guidelines, despite ongoing con-
troversy concerning the effect of follow-up on overall 
survival. The available evidence on the clinical effec-
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tiveness of CEA as a tumor marker in the follow-up 
after curative treatment of CRC is based on four re-
views and a Cochrane meta-analysis, with much over-
lap of included studies (Bruinvels et al. 1994, Jeffery 
et al. 2007, Kievit et al. 2000, Renehan et al. 2002, 
Tjandra & Chan 2007). The Cochrane review, includ-
ing only prospective trials, failed to define the best use 
of CEA in follow-up, but did show that studies with 
frequent CEA measurements are associated with 
longer survival. Diagnostic accuracy of CEA in follow
-up is influenced by the chosen cut-off or threshold 
value. Although the best way to use CEA is yet to be 
defined, the rise rather than the absolute value is an 
important indicator for recurrent disease activity 
(Grossmann et al. 2011). Currently, CEA is the only 
recommended tumor marker to be used in follow-up in 
Europe and the United States (Duffy et al. 2007, Eche 
et al. 2001, , www.oncoline.nl). 
 The search for better tumor markers as indica-
tors of recurrent disease is ongoing. Monoclonal anti-
body technology has permitted the identification of 
new tumor markers, such as Carbohydrate Antigens 
(CA 19-9, CA 242, CA 50), which show variable re-
sults since their introduction in the 1980’s and 1990’s. 
Lately nucleic acid markers, which are markers con-
sisting of tumor-derived circulating DNA in serum, 
mRNA and microRNA, have become a subject of in-
terest (Schwarzenbach et al 2011). These markers are 
associated with the presence of various solid tumors 
including CRC (Goebel et al. 2005) and preoperative 
rise in several serum nucleic acid markers has proven 
to predict both prognosis and metastasis in CRC  
(Herbst et al. 2009, Lecomte et al. 2002). Proliferative 
markers are also applied, such as the protein antigen 
Tissue Polypeptide Antigen (TPA) which is synthe-
sized by tissues undergoing rapid growth. In addition, 
the ability of tumor cells to degrade the extracellular 
matrix (ECM) has been used by measuring analytes 
involved in ECM function as tumor markers 
(Golovkov 2009). 
 
Aim 
 
Given the gain in survival which can be obtained by 
finding recurrences in an early stage, there is a need 
for a tumor marker that indicates recurrent disease. 
The aim of this diagnostic review article is to examine 
the current literature on quantitative tumor markers in 
human blood samples which have been serially meas-
ured for use in follow-up in CRC and to compare their 
clinical value with CEA measurements. Therefore, we 
analyzed all available literature on quantitative mark-
ers that were serially measured during follow-up of 
CRC. 
Materials and Methods 
 
Systematic literature search and primary outcomes 
A comprehensive review of the literature (1985 - 2010) 
was performed using multiple electronic search en-
gines including PubMed, Embase and the Cochrane 
Database. The MeSH search term [tumor marker] 
AND [Colorectal neoplasm] were used, limited to 
‘English language’, ‘Humans’, and ‘Adult’, and with 
exclusion of “Chemotherapy”. The ‘related articles’ 
function in PubMed was also used. Additional relevant 
references found in articles were included. Review 
articles and letters were used as a reference but not 
included in the analysis. Abstracts were selected on 
available information concerning the use of tumor 
markers in follow-up after curative resection of CRC.  
 Inclusion criteria were [1] curative treatment 
of any stage of CRC, [2] postoperative surveillance 
with serial tumor marker measurements in addition to 
CEA itself, i.e., the marker of interest was quantita-
tively measured more than once during follow-up, [3] 
availability of sensitivity data of the tumor marker in 
indicating recurrent disease and [4] quality score ≥ 4 
(Figure 1).  
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Criterion 
Points if 
Yes 
Points 
if No 
1. Is the population under 
study defined with in- and 
exclusion criteria? 
1 0 
2. Were patient data 
prospectively collected? 
1 0 
3. Are the main prognostic 
patient and tumour 
characteristics presented? 
1 0 
Is the antibody used 
specified? 
1 0 
Are control samples and a 
cut-off value for positive 
expression specified? 
1 0 
5. Is the study endpoint 
defined? 
1 0 
6. Is the time of follow-up 
specified? 
1 0 
7. Is loss during analysis 
or follow up described? 
1 0 
Figure 1. Criteria for quality assessment of a study. The 
maximum score is 8.  
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 Sensitivity is the percentage of patients cor-
rectly identified as having the condition by rise in the 
tumor marker, while specificity is the percentage of 
healthy people correctly identified as not having the 
condition by no rise in tumor marker. Sensitivity and 
specificity of the markers investigated in each article 
were recalculated using the following equations: 
(1) Sensitivity = 100% X (true positives) / (true posi-
tives + false negatives) 
(2) Specificity = 100% X (true negatives) / (true nega-
tives + false positives) 
Studies were excluded [1] when the full text of the ar-
ticle was not accessible at our institution, [2] when the 
investigated marker was only qualitatively reported 
(i.e. absent or present) or [3] when the study only con-
cerned CEA as a marker.  
 
Study quality assessment 
Two investigators (CJV and WHJ) independently ex-
tracted data from the included studies. Inconsistencies 
were resolved by consensus. A standardized character-
istics and result abstraction form was used to collect 
descriptive patient data, type of tumor and tumor stage, 
study design, follow-up schemes, assays and cut-off 
values. Study quality was assessed independently by 
the two investigators applying a predefined form with 
face validity, which was derived from McShane  
(McShane et al. 2005) and used earlier by de Graeff 
(de Graeff et al. 2009, Figure 1). This resulted in a 
quality score with a minimum of 0 points and a maxi-
mum of 8 points. 
 
Results 
 
In total, 224 articles were identified using the above 
keywords and restrictions. Title and abstract review 
resulted in the exclusion of 187 articles, which means 
that 37 articles were searched in full. The process is 
visualized in Figure 2. After applying the quality re-
strictions described previously, seventeen studies re-
mained, investigating 8 additional markers. In Table 1, 
an overview of the included studies is shown, focusing 
on the value of the tumor markers in finding recurrent 
disease (Barillari et al. 1992, 1991, Engaras 2003, Fer-
nandes et al. 2006, Filella et al. 1994, Fucini et al. 
1987, Griesenberg et al. 1999, Guadagni et al. 1993, 
Hall et al. 1994, Holubec et al. 2000, Morita et al. 
2004, Nicolini et al. 1995, 2010, Park et al. 2009, 
Plebani et al. 1997, Spila et al. 2001, Yakabe et al. 
2010). The different markers are CA19-9, CA242, 
CA72-4, CA-195, CA-50, TPA (or TPS), C-terminal 
peptide (PIP), and N-terminal peptide (PIIIP), the latter 
two being markers of ECM synthesis. The studies 
comprised 2594 patients in total (range 24-700 per 
study). Mean quality score was 4.8 points. 
 
Follow up schedules  
Patients entered the follow-up program in all studies 
after curative treatment. Generally, blood samples 
were drawn at each follow-up outpatient visit, and sur-
veillance was performed on a 3- or 6-monthly basis. 
This schedule is the common guideline in all countries 
from which study data were collected. In 2 studies, 
there was no strict protocol for tumor marker measure-
ments. Patients from these studies were included if 
they had serial measurements of the marker in follow-
up for a pre-defined number of years (Nicolini et al. 
1995, Spila et al. 2001). In 14 studies follow-up sched-
ules were strict and well-described. The length of fol-
low-up differed per study. Unfortunately the numbers 
of patients lost to follow-up are not mentioned in most 
studies, which was reflected in our quality score as-
sessment. In Table 1, follow-up schedules are men-
tioned and further commented on. 
 
Cut-off values and assays 
The cut-off values and assays used per tumor marker 
are shown in Table 2. In this table the recalculated sen-
sitivity and specificity for the marker of interest are 
also given. For the marker that was most intensively 
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Figure 2. Inclusion form. Adapted from Moher et al. 2009. 
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investigated, CA 19-9, 6 different assays were used 
(CIS Biomedical, Abbott, Sorin, Mitsubishi, Centocor, 
and Bayer) using 2 different cut-off values. In one 
study cut-off levels were variable, calculated per out-
come group with a fixed specificity of 95% (Holubec 
et al. 2000). For this study calculated and recalculated 
sensitivities and specificities are added.  
 
Best marker 
For studies reporting on tumor markers with a sensitiv-
ity of more than 60% a separate overview is shown in 
Table 3. It demonstrates sensitivity and specificity of 
both markers and CEA as found in the same article. 
Studies with higher sensitivities for the investigated 
marker than for CEA are highlighted.  
 Results in Table 3 show that, according to two 
studies, TPA is a better marker in finding recurrent 
disease than CEA. Furthermore, the combination of 
CEA with an additional marker in several combina-
tions increases the sensivitiy for detection of recurrent 
disease. Barillari performed a well-described prospec-
tive study on TPA, which showed high sensitivity 
(79%) and low false-positive rates. This study was, 
however, restricted to rectal cancer (Barillari et al. 
1992). Fernandes performed a study on TPA with dif-
ferent study design and assay methods, calculating the 
sensitivity and specificity per rise in TPA with Re-
ceiver-Operator Curves (ROC). He found a bigger area 
under the curve for TPA than for CEA, especially in 
the first postoperative year (Fernandes et al. 2006). 
 For two other markers higher or similar sensi-
tivity was shown than for CEA: CA 242 and CA 72-4 
(Guadagni et al. 1993, Nicolini et al. 1995, Spila et al. 
2001). Guadagni performed one of the first prospective 
studies for CA after introducing monoclonal antibody 
technology on patients with both benign and malignant 
disease (n=300). He also performed a sub-analysis of 
recurrent malignant disease (n=51), thereby finding a 
sensitivity of 83% for CA 72-4 and a positive predict-
ing value of 100% (Guadagni et al. 1993). Spila et al 
performed a similar longitudinal analysis on CA 242 in 
which both benign and malignant diseases (n=630) 
were included with sub-analysis of 50 patients with 
recurrent malignant disease. Although CA 242 showed 
a slightly better sensitivity in finding these recurrences 
than CEA, the overall increase of sensitivity after addi-
tion of CA 242 and CA 19-9 to that of CEA alone was 
about 8% with a false positive rate of 36% (Spila et al. 
2001). 
 
Discussion 
 
Main results 
Our review comprised the available literature consider-
ing the follow-up of CRC, focusing on serially and 
quantitatively measured tumor markers. Four studies 
concluded that markers other than CEA had higher 
sensitivities than CEA itself (Barillari et al. 1992, Fer-
nandes et al. 2006,  Guadagni et al. 1993, Spila et al. 
2001), with sensitivities higher than 60%. 
 The finding of TPA as a tumor marker was a 
surprising finding; in the Netherlands most studies 
have focused on immunological rather than prolifera-
tive markers and measurement of TPA serially is un-
usual. In two independent studies TPA showed to have 
higher sensitivity than CEA for recurrence of CRC 
(Barillari et al. 1992, Fernandes et al. 2006). TPA is a 
constituent of the epithelial cells of many hollow or-
gans, and is found in tissues undergoing rapid growth, 
such as tumor cells. Measurement of serum TPA is 
relatively cheap, TPA is measured by an easily acces-
sible technique, and is therefore broadly available. 
However, both studies have been performed more than 
5 years ago. Recently (in 2010) Nicolini failed to es-
tablish the accuracy of TPA. When used as an individ-
ual tumor maker, TPA’s level was increased in 8/32 
recurrences (sensitivity 25%). When integrated in a 
tumor marker panel together with CEA, TPA resulted 
in an increase of CEA sensitivity from 46% to 79% 
(Nicolini et al. 2010).  
 A well-performed large study on CA 19-9 
failed to show higher recurrence detection than with 
CEA as a tumor marker (sensitivity 43% vs. sensitivity 
63%). However, its sensitivity was increased when 
individual cut-off values were applied, based on the 
lowest postoperative value corrected for inter-assay 
variation (Engaras 2003). As for CA 72-4, newer stud-
ies did not confirm the clinical use of this marker 
(Carpelan-Holmstrom et al. 2004, Holubec et al. 
2000).  
 
Points of discussion 
In all patients included in our review postoperative 
serial measurements were performed, independent of 
the preoperative marker level (which was in some 
studies not measured at all). The relationship between 
the preoperative value of CEA and the secretion of 
CEA by recurrences is still under debate. Several stud-
ies conclude that postoperative surveillance with CEA 
is useful regardless of the preoperative value. These 
studies strengthen our conviction that serial measure-
ments of other markers of interest are also useful when 
the preoperative value is not known (Grossmann et al. 
2007, Zeng et al. 1993). 
 The currently emerging class of molecular tu-
mor markers includes circulating nucleic acids, epige-
netic alterations, gene-expression profiles and analysis 
of circulating cancer cells. We realize that by exclud-
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ing histologically estimated markers and qualitative 
markers, most of these new tumor markers have not 
been included in this review. However, by applying 
strict inclusion criteria we avoided creating a selection 
bias and thus, the comparability of studies is more reli-
able. Furthermore the use of serum measurements in 
daily practice is common and easy in comparison to 
the use of histological markers. 
 Tumor marker panels are relatively new and 
promising in the follow-up of colorectal cancer. Addi-
tive value on indicating recurrence is often found, sug-
gesting panels could outperform routine imaging tech-
niques in follow-up, with favorable financial perspec-
tives. Recent evaluation of an extensive tumor marker 
panel demonstrated an increase in sensitivity in finding 
recurrences (Nicolini et al. 2010). Sensitivity was 
raised from 47% to 71% by adding TPA to CEA meas-
urements. In the current review, the additional value of 
tumor marker panels has also been shown. 
 Specificity of tumor markers is the number of 
patients without recurrence who are correctly identi-
fied by the tumor marker as not having a recurrence. It 
is known that some tumor markers not only increase in 
case of recurrent disease, but also in several non-
malignant processes such as infection and smoking 
(van Larebeke et al. 2003). The studies showing a high 
sensitivity for TPA demonstrated specificities of 61 
and 72%, which we considered acceptable. 
 
Limitations 
Differences in study designs regarding patient and tu-
mor stage selection and follow-up schedules influences 
our conclusions. The authors recognize that the com-
parison of different designs is the main weakness of 
our study. However, criteria for patient selection and 
follow-up schedules have not yet been standardized. 
We tried to overcome this bias issue by applying strict 
study selection using standardized study criteria and 
two independent reviewers. In addition the review was 
constructed following the REMARK guidelines 
(McShane et al. 2005). We excluded studies with qual-
ity scores that were too low according to these guide-
lines. Furthermore, it is important to realize that only 
serially and quantitatively measured follow-up markers 
were considered in this review. Since nucleic acid 
markers are qualitative markers, most of these were 
excluded; they either are present or absent. Conse-
quently, bias resulting from different study designs 
was diminished. 
 The “cut-off” level determines sensitivity and 
specificity of the tumor marker. Therefore, the diag-
nostic accuracy of the marker depends on the cut-off 
level applied. In addition, comparability of data is in-
fluenced by this cut-off level. A variety of markers 
measured with several assays were included; cut-off 
values differed per study, therefore resulting in bias. In 
all except one study immunoassays were used for 
quantification of test results. In the one study that did 
not, various cut-off values were tested to obtain the 
value with the highest sensitivity. Immunoassays are 
known to have high analytical sensitivity, which 
means low concentrations can be measured reliably. 
Other strengths of immunoassays are the potential of 
full automation and its practicability, with relative lit-
tle technical expertise required. The main problem in 
comparing immunoassay results, however, is the fact 
that results obtained from each commercial available 
assay depend on their own antibody with its specific 
characteristics. This leads to different cut-off values 
and reference values for a single marker and compli-
cates inter-laboratory comparability. Also the inter- 
and intra-assay variability of the commercially ob-
tained assays causes difficulties for patient follow-up 
studies (Wood 2008). 
 
Future perspectives 
Although TPA shows to be promising in outperform-
ing CEA in finding colorectal recurrences, no conclu-
sive prospective clinical trial has been performed. A 
recent study showed an increase in finding curable me-
tastases with intensive surveillance using a tumor 
marker panel including TPA (Nicolini et al. 2010), but 
we did not find conclusive studies on the value of TPA 
alone. As there is no definitive consensus regarding the 
postoperative surveillance after curative resection for 
colorectal cancer, we propose a large prospective fol-
low-up trial focusing on the true value of TPA in colo-
rectal cancer follow-up. 
 At this time, a national trial with frequent CEA 
testing and CEA-triggered imaging in follow-up is per-
formed in the Netherlands (Netherlands Trial Register 
(NTR) 2182). Serum samples of the included patients 
in this large trial are being stored in a Biobank, and 
since clinical conditions of all patients are well-
described, this enables us to test sensitivity and speci-
ficity of TPA in addition to a tumor marker panel con-
sisting of both CEA and TPA (and other possible new 
markers of interest). All patient characteristics includ-
ing tumor stage will be registered. Advantages of the 
Biobank would be the uniform strategy in which all 
sera are analyzed with the same assay, and that all pa-
tients undergo the same study regimen and design. 
Based on the results of this review, we could start with 
TPA measurements and subsequently measure other 
promising markers.   
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